Aflibercept treatment in patients with diabetic macular edema

The article provides a brief description of diabetic macular edema pathogenesis highlighting the role of inflammation, along with a short review of aflibercept trials in diabetic macular edema patients. Three clinical cases of diabetic macular edema treatment with aflibercept (Eylea) intravitreal injections in treatment-naive patients are described; therapy was performed for 1 year according to the scheme provided in the Summary of Product Characteristics.